MyoScience raises $10.4M for aesthetic medicine
MyoScience, a stealth-mode medical company based in Redwood City, Calif., has taken $10.4 million in a second funding for continuing clinical trials.
The company has not yet disclosed exactly what use its aesthetic devices will have, although CEO Lisa Elkins hinted that aging eyes and skin… Continue Reading
Life-science briefing: Tuesday, April 8, 2008
TODAY’S HEADLINES:
AGI Dermatics takes in $5M for skincare products (release)
Myconostica raises £3.9 for fungal diagnostics (GenomeWeb)
Germany’s Noxxon gets €1M grant for aptamer drugs (release)
AGI Dermatics takes in $5M for skincare products – Freeport, N.Y.-based AGI Dermatics, a startup concentrated on skincare products, raised $5 million in… Continue Reading
Life sciences briefing: Thursday, Feb. 7, 2008
TODAY’S HEADLINES:
Aptamer-drug maker Archemix withdraws its $72.5 million IPO (Edgar)
OraMetrix raises $20M for robotic orthodontic systems (peHUB)
Microarray maker TeleChem goes public via reverse merger (release)
BioVascular pulls in $11M for platelet-disease treatments (release)
Cequent Pharma adds $4.5M for for RNAi drugs (VentureWire)
CareSeek, online medical-rating service, gets $575K,… Continue Reading
Life sciences briefing: Wednesday, Aug. 29, 2007
(UPDATED at 3:10pm PT: See below.)
Featured companies: Agendia, EndoGastric Solutions, FlowCo, Gentris, MedManage Systems, ParagonDx, Presidio Pharmaceuticals, Xoova
Presidio Pharma raises $26M for viral treatments — San Francisco’s Presidio Pharmaceuticals, a biotech developing new antiviral drugs, raised $26 million in a second funding round. Investors included Panorama… Continue Reading
Life sciences briefing: Friday, Aug. 10, 2007
(CORRECTED: See below.)
Featured companies: VistaGen Therapeutics, MindWeavers, Cutanea Life Sciences, Heptares Therapeutics
VistaGen raises $3.75M for stem-cell based drug discovery — South San Francisco, Calif.-based VistaGen Therapeutics, a biotech that uses human embryonic stem cells to discover new drugs, raised $3.75 million in a bridge financing as it… Continue Reading
Cequent Pharma raises $9 million for RNAi
Cequent Pharmaceuticals, a Cambridge, Mass., developer of drugs based on a new gene-silencing technology, raised $9 million in a first-round funding. The round was led by the Novartis Option Fund, joined by Ampersand Ventures, Nexus Medical Partners, and Pappas Ventures.
Cequent is developing new treatments based… Continue Reading